In this installment of Quva Talks, Vice President of Pharmacy Operations, Amber Lucas draws on nearly 30 years leading hospital pharmacy teams to clear up one of the most common misconceptions in sterile compounding: that hospital compounding under USP <797> is the same as 503B outsourcing facility manufacturing. She explains why the two are built for different purposes, and what that distinction means for the medications hospital pharmacy teams rely on every day.
USP <797> vs. 503B Manufacturing: What's the Difference?
Hospitals prepare medications under USP <797> to meet immediate patient needs. A 503B outsourcing facility operates under current Good Manufacturing Practices (cGMP), with extensive documentation, testing, validation, and quality controls built to deliver consistent products at scale.
Why Labeling and Batch Documentation Matter
Lucas points to two safeguards behind every product a hospital pharmacy receives: clear, compliant labeling that helps clinicians quickly and safely identify medications during high-pressure moments of patient care, and complete batch documentation that provides full traceability from raw materials through final release.
Giving Pharmacy Teams More Time for Patient Care
For Lucas, the goal of 503B manufacturing isn't just producing sterile medications - it's helping pharmacy teams spend less time worrying about product quality and more time focused on patient care.